Cjc 1295 Ipamorelin Gh Pulse Stack (peptidedosingprotocols.com)

How it works

The CJC-1295 + Ipamorelin stack is the most widely planned growth hormone (GH) peptide combination in the research community. CJC-1295 mimics the body's GHRH signal, telling the pituitary gland to make GH. Ipamorelin works through a separate ghrelin receptor pathway, telling the pituitary to release GH. Two different signals on the same target cell.

CJC-1295 is a 30-amino-acid GHRH analog. It binds GHRH receptors on pituitary somatotrophs, the cells that produce GH. Its short half-life (30 minutes to 2 hours) preserves the body's natural pulsatile signaling pattern. Think of it as the production-side signal: tell the pituitary to make GH and prepare to release it.

Ipamorelin is a 5-amino-acid pentapeptide that binds the ghrelin receptor (GHSR1a) on the same pituitary cells. Activating that receptor triggers a calcium-dependent release of GH that amplifies whatever GHRH signaling is already in progress. Think of it as the release-side signal: trigger the actual GH pulse.

Cellular work suggests these two pathways do not just add up — they multiply. A 2002 study (Cunha & Mayo) showed that active ghrelin-receptor signaling potentiates GHRH signaling on the same cell. This synergistic effect is widely described in preclinical and pharmacology literature, although no published human RCT has tested the exact blend at common research-planning doses.

Older growth hormone secretagogues like GHRP-2 and GHRP-6 also bind the ghrelin receptor, but they elevate cortisol, prolactin, and appetite. Ipamorelin does not. Raun et al. (1998) showed no significant cortisol or ACTH elevation even at 200 times the effective GH-releasing dose. This selectivity is the reason Ipamorelin became the default GHRP for research planning. [Source: Peptide Dosing Protocols]

Plain language: CJC-1295 and Ipamorelin work together by signaling the pituitary gland to produce and release growth hormone through different pathways, enhancing each other's effects.

Who should avoid it

Anyone with active or prior cancer, pituitary disease, diabetic retinopathy, severe kidney disease, or who is pregnant/breastfeeding should not use GH-stimulating peptides. This is due to the potential for GH and IGF-1 to promote cell proliferation, which could exacerbate cancer risks. Additionally, individuals experiencing carpal tunnel-style symptoms (tingling, numbness in hands) should reduce their dose or pause, as this may indicate excessive GH or IGF-1 levels. Those with diabetes, insulin resistance, or pre-diabetes need to monitor their blood glucose closely, as GH is counter-regulatory to insulin. Persistent joint pain beyond the first two weeks of use is another signal to reduce the dose. [Source: Peptide Dosing Protocols]

Plain language: People with certain health conditions like cancer or diabetes should avoid using this stack.